...
机译:HLA-DRB1 * 04:05在两种案例中,由持续施用Nivolumab和Dabrafenib / Trametinib疗法治疗的先进黑色素瘤患者的vogt-koyanagi-harada疾病样葡萄膜炎
Tohoku Univ Grad Sch Med Dept Dermatol Sendai Miyagi Japan;
Tohoku Univ Grad Sch Med Dept Dermatol Sendai Miyagi Japan;
Tohoku Univ Grad Sch Med Dept Dermatol Sendai Miyagi Japan;
Tohoku Univ Grad Sch Med Dept Dermatol Sendai Miyagi Japan;
Tohoku Univ Grad Sch Med Dept Dermatol Sendai Miyagi Japan;
Kyoto Univ Grad Sch Med Dept Dermatol Kyoto Japan;
HLA Fdn Lab Kyoto Japan;
Tohoku Univ Grad Sch Med Dept Dermatol Sendai Miyagi Japan;
Tohoku Univ Grad Sch Med Dept Dermatol Sendai Miyagi Japan;
Tohoku Univ Grad Sch Med Dept Dermatol Sendai Miyagi Japan;
advanced melanoma; immune-related adverse events; immunotherapy; molecular-targeting therapy; Vogt-Koyanagi-Harada disease-like uveitis;
机译:HLA-DRB1 * 04:05在两种案例中,由持续施用Nivolumab和Dabrafenib / Trametinib疗法治疗的先进黑色素瘤患者的vogt-koyanagi-harada疾病样葡萄膜炎
机译:在由Pembrolizumab治疗的晚期黑色素瘤患者中发育严重的横纹肌分解,其次是Dabrafenib Trametinib联合治疗
机译:两种Dabrafenib和Trametinib治疗疗法 - 失败的晚期黑色素瘤被Nivolumab单药治疗成功控制
机译:Dabrafenib Plus Trametinib与Nivolumab对德国佐剂治疗辅助治疗患者患者患者的经济评价
机译:用DabrafeNib + Trametinib与Nivolumab或Pembrolizumab单药治疗患者转移性黑素瘤患者的医疗资源利用